Clinical Trial Update: Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of disitamab vedotin and abiraterone for metastatic castration-resistant prostate cancer; recruitment is ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: mCRPC | Phase 2 | Status: RECRUITING